The FOURIER and ODYSSEY OUTCOMES demonstrated the benefit of PCSK9 monoclonal antibodies on cardiovascular events in patients with stable CAD, which is primarily driven by more profound LDL-C lowering. This evidence concerns the gene PCSK9 and coronary artery disorder.